(VIANEWS) – Shares of FibroGen (NASDAQ: FGEN) dropped 9.53% to $18.45 at 12:08 EST on Monday, following the last session’s upward trend. NASDAQ is falling 0.56% to $12,004.82, following the last session’s upward trend. This seems, as yet, a somewhat bearish trend trading session today.
FibroGen’s last close was $20.40, 20.59% under its 52-week high of $25.69.
About FibroGen
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Earnings Per Share
As for profitability, FibroGen has a trailing twelve months EPS of $-3.06.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -258.01%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
FibroGen’s EBITDA is -18.23.
Volume
Today’s last reported volume for FibroGen is 435228 which is 48.33% below its average volume of 842463.
Revenue Growth
Year-on-year quarterly revenue growth grew by 107.7%, now sitting on 140.73M for the twelve trailing months.
More news about FibroGen (FGEN).
